Why the study?
It was unclear whether newly diagnosed cancer adds to arterial thromboembolism risk in AF patients with low to intermediate CHA2DS2-VASc scores.
Does newly diagnosed cancer increase the risk of arterial thromboembolism in patients with atrial fibrillation and a CHA2DS2-VASc score of 0 to 2?
Does newly diagnosed cancer increase the risk of arterial thromboembolism in patients with atrial fibrillation and a CHA2DS2-VASc score of 0 to 2?
Newly diagnosed cancer is associated with a significantly increased risk of arterial thromboembolism in AF patients with low-to-intermediate CHA2DS2-VASc scores (0-2) who are not on anticoagulation.
Answers are grounded in this paper and cite their sources.
Newly diagnosed cancer was associated with higher ATE risk in low CHA2DS2-VASc AF; leaves open whether anticoagulation thresholds warrant revision.
It is unclear whether newly diagnosed cancer adds to the risk of arterial thromboembolism (ATE) in patients with atrial fibrillation/flutter (AF). This is especially relevant for AF patients with low to intermediate CHA2DS2-VASc scores in whom the risk-benefit ratios between ATE and bleeding are delicately balanced. We sought to evaluate ATE risk in AF patients with a CHA2DS2-VASc score of 0 to 2 with and without cancer. A population-based retrospective cohort study was performed. Patients with a CHA2DS2-VASc score of 0 to 2 not receiving anticoagulation at cancer diagnosis (or the matched index date) were included. Patients with embolic ATE or cancer before study index were excluded. AF patients were categorized into AF and cancer and AF and no cancer cohorts. Cohorts were matched for multinomial distribution of age, sex, index year, AF duration, CHA2DS2-VASc score, and low/high/undefined ATE risk cancer. Patients were followed from study index until the primary outcome or death. The primary outcome was acute ATE (ischemic stroke, transient ischemic attack, or systemic ATE) at 12 months using International Classification of Diseases-Ninth Revision codes from hospitalization. The Fine-Gray competing risk model was used to estimate the HR for ATE with death as a competing risk. The 12-month cumulative incidence of ATE was 2.13% (95% CI: 1.47-2.99) in 1411 AF patients with cancer and 0.8% (95% CI: 0.56-1.10) in 4,233 AF patients without cancer (HR: 2.70; 95% CI: 1.65-4.41). The risk was highest in men with CHA2DS2-VASc = 1 and women with CHA2DS2-VASc = 2 (HR: 6.07; 95% CI: 2.45-15.01). In AF patients with CHA2DS2-VASc scores of 0 to 2, newly diagnosed cancer is associated with an increased incidence of stroke, transient ischemic attack, or systemic ATE compared with matched controls without cancer.
No takes yet. Share an insight, caveat, or question.
Leader et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: